104 related articles for article (PubMed ID: 38532108)
21. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.
Theruvath J; Menard M; Smith BAH; Linde MH; Coles GL; Dalton GN; Wu W; Kiru L; Delaidelli A; Sotillo E; Silberstein JL; Geraghty AC; Banuelos A; Radosevich MT; Dhingra S; Heitzeneder S; Tousley A; Lattin J; Xu P; Huang J; Nasholm N; He A; Kuo TC; Sangalang ERB; Pons J; Barkal A; Brewer RE; Marjon KD; Vilches-Moure JG; Marshall PL; Fernandes R; Monje M; Cochran JR; Sorensen PH; Daldrup-Link HE; Weissman IL; Sage J; Majeti R; Bertozzi CR; Weiss WA; Mackall CL; Majzner RG
Nat Med; 2022 Feb; 28(2):333-344. PubMed ID: 35027753
[TBL] [Abstract][Full Text] [Related]
22. Targeting CD47 for cancer immunotherapy.
Jiang Z; Sun H; Yu J; Tian W; Song Y
J Hematol Oncol; 2021 Oct; 14(1):180. PubMed ID: 34717705
[TBL] [Abstract][Full Text] [Related]
23. Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View.
Körfer J; Lordick F; Hacker UT
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680363
[TBL] [Abstract][Full Text] [Related]
24. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
25. Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers.
Lu Z; Peng Z; Liu C; Wang Z; Wang Y; Jiao X; Li J; Shen L
Innovation (Camb); 2020 Aug; 1(2):100041. PubMed ID: 34557714
[TBL] [Abstract][Full Text] [Related]
26. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY; Shitara K; Moehler M; Garrido M; Salman P; Shen L; Wyrwicz L; Yamaguchi K; Skoczylas T; Campos Bragagnoli A; Liu T; Schenker M; Yanez P; Tehfe M; Kowalyszyn R; Karamouzis MV; Bruges R; Zander T; Pazo-Cid R; Hitre E; Feeney K; Cleary JM; Poulart V; Cullen D; Lei M; Xiao H; Kondo K; Li M; Ajani JA
Lancet; 2021 Jul; 398(10294):27-40. PubMed ID: 34102137
[TBL] [Abstract][Full Text] [Related]
27. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
28. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
Saeed A; Park R; Sun W
J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
[TBL] [Abstract][Full Text] [Related]
29. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.
Bagchi S; Yuan R; Engleman EG
Annu Rev Pathol; 2021 Jan; 16():223-249. PubMed ID: 33197221
[TBL] [Abstract][Full Text] [Related]
30. Gastric cancer.
Smyth EC; Nilsson M; Grabsch HI; van Grieken NC; Lordick F
Lancet; 2020 Aug; 396(10251):635-648. PubMed ID: 32861308
[TBL] [Abstract][Full Text] [Related]
31. Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity.
Wang Y; Ni H; Zhou S; He K; Gao Y; Wu W; Wu M; Wu Z; Qiu X; Zhou Y; Chen B; Pan D; Huang C; Li M; Bian Y; Yang M; Miao L; Liu J
Cancer Immunol Immunother; 2021 Feb; 70(2):365-376. PubMed ID: 32761423
[TBL] [Abstract][Full Text] [Related]
32. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
Fukuoka S; Hara H; Takahashi N; Kojima T; Kawazoe A; Asayama M; Yoshii T; Kotani D; Tamura H; Mikamoto Y; Hirano N; Wakabayashi M; Nomura S; Sato A; Kuwata T; Togashi Y; Nishikawa H; Shitara K
J Clin Oncol; 2020 Jun; 38(18):2053-2061. PubMed ID: 32343640
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity.
von Roemeling CA; Wang Y; Qie Y; Yuan H; Zhao H; Liu X; Yang Z; Yang M; Deng W; Bruno KA; Chan CK; Lee AS; Rosenfeld SS; Yun K; Johnson AJ; Mitchell DA; Jiang W; Kim BYS
Nat Commun; 2020 Mar; 11(1):1508. PubMed ID: 32198351
[TBL] [Abstract][Full Text] [Related]
34. Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice.
Li Y; Zhang M; Wang X; Liu W; Wang H; Yang YG
Nat Commun; 2020 Jan; 11(1):581. PubMed ID: 31996683
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Marabelle A; Le DT; Ascierto PA; Di Giacomo AM; De Jesus-Acosta A; Delord JP; Geva R; Gottfried M; Penel N; Hansen AR; Piha-Paul SA; Doi T; Gao B; Chung HC; Lopez-Martin J; Bang YJ; Frommer RS; Shah M; Ghori R; Joe AK; Pruitt SK; Diaz LA
J Clin Oncol; 2020 Jan; 38(1):1-10. PubMed ID: 31682550
[TBL] [Abstract][Full Text] [Related]
36. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
Shigeta K; Datta M; Hato T; Kitahara S; Chen IX; Matsui A; Kikuchi H; Mamessier E; Aoki S; Ramjiawan RR; Ochiai H; Bardeesy N; Huang P; Cobbold M; Zhu AX; Jain RK; Duda DG
Hepatology; 2020 Apr; 71(4):1247-1261. PubMed ID: 31378984
[TBL] [Abstract][Full Text] [Related]
37. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
38. Combinations of Bevacizumab With Cancer Immunotherapy.
Chen DS; Hurwitz H
Cancer J; 2018; 24(4):193-204. PubMed ID: 30119083
[TBL] [Abstract][Full Text] [Related]
39. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.
Meder L; Schuldt P; Thelen M; Schmitt A; Dietlein F; Klein S; Borchmann S; Wennhold K; Vlasic I; Oberbeck S; Riedel R; Florin A; Golfmann K; Schlößer HA; Odenthal M; Buettner R; Wolf J; Hallek M; Herling M; von Bergwelt-Baildon M; Reinhardt HC; Ullrich RT
Cancer Res; 2018 Aug; 78(15):4270-4281. PubMed ID: 29776963
[TBL] [Abstract][Full Text] [Related]
40. Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma.
Zhang X; Chen W; Fan J; Wang S; Xian Z; Luan J; Li Y; Wang Y; Nan Y; Luo M; Li S; Tian W; Ju D
Carcinogenesis; 2018 May; 39(5):689-699. PubMed ID: 29538621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]